Clinical Differences Between ARBs
All ARBs are clinically equivalent for blood pressure reduction and share the same class-wide contraindications and side effects, with differences primarily in dosing frequency, specific FDA-approved indications beyond hypertension, and potentially in receptor occupancy profiles. 1, 2, 3
Dosing and Administration
The ARBs differ primarily in their dosing ranges and frequency:
Once-daily agents:
- Azilsartan: 40-80 mg daily (highest potency per mg)
- Candesartan: 8-32 mg daily
- Irbesartan: 150-300 mg daily
- Olmesartan: 20-40 mg daily
- Telmisartan: 20-80 mg daily
- Valsartan: 80-320 mg daily
Once or twice-daily agents:
- Losartan: 50-100 mg in 1-2 divided doses
- Eprosartan: 600-800 mg in 1-2 divided doses
FDA-Approved Indications Beyond Hypertension
While all ARBs treat hypertension, specific agents have additional evidence-based indications:
Heart Failure with Reduced Ejection Fraction:
- Candesartan: 4-8 mg starting dose, titrate to 32 mg daily 4, 5, 4
- Losartan: 25-50 mg starting dose, titrate to 50-100 mg daily 4
- Valsartan: 20-40 mg twice daily starting dose, titrate to 160 mg twice daily 4, 5, 4
These three ARBs have demonstrated mortality and morbidity reduction in heart failure patients intolerant to ACE inhibitors 5, 4.
Post-Myocardial Infarction:
- Valsartan: Demonstrated non-inferior benefit to ACE inhibitors in patients with LV dysfunction after MI 6, 4
Diabetic Nephropathy:
- Irbesartan: 150-300 mg daily - proven renoprotective effects in type 2 diabetes with nephropathy 7, 8
- Losartan: 25-100 mg daily - demonstrated renal protection in diabetic nephropathy 7
Side Effect Profile
Class-wide effects (identical across all ARBs):
- Hyperkalemia risk (especially with CKD, K+ supplements, or K+-sparing drugs)
- Acute renal failure risk with bilateral renal artery stenosis
- Contraindicated in pregnancy
- Hypotension
- Renal dysfunction 1, 2, 3
Angioedema: Much less frequent than with ACE inhibitors (<1% vs up to 20% cough with ACEIs), but can still occur. If a patient had angioedema with an ACE inhibitor, wait 6 weeks before starting an ARB and use extreme caution 1, 2, 3, 4.
Critical distinction: ARBs do NOT cause the persistent dry cough seen with ACE inhibitors (up to 20% incidence) because they don't inhibit kininase 5, 4. This is the primary tolerability advantage.
Receptor Occupancy and Potency Differences
Recent evidence suggests pharmacologic differences exist:
Higher receptor occupancy (potentially greater pleiotropic effects):
- Olmesartan and telmisartan appear to provide superior 24-hour blood pressure control in some comparative trials 9, 10
- Irbesartan showed higher trough receptor occupancy compared to valsartan and candesartan in one study 11
Lower efficacy in some trials:
- Losartan and valsartan were less effective at blood pressure reduction than newer agents (olmesartan, telmisartan) in head-to-head comparisons 9, 10
However, these differences are modest and do not translate to different cardiovascular outcomes when used at appropriate doses 1, 2, 3.
Key Clinical Caveats
Do NOT combine:
- ARB + ACE inhibitor + renin inhibitor (potentially harmful) 3
- Two ARBs together (no benefit, increased harm) 1, 2, 3
Monitoring requirements (identical for all ARBs):
- Recheck blood pressure, renal function, and potassium within 1-2 weeks of initiation or dose changes
- Particular vigilance needed with: systolic BP <80 mmHg, low sodium, diabetes, impaired renal function 4
Practical selection: Choose based on:
- Specific indication (heart failure → candesartan/losartan/valsartan; diabetic nephropathy → irbesartan/losartan)
- Dosing convenience (once-daily preferred for adherence)
- Cost and formulary availability
- Prior ACE inhibitor intolerance (any ARB appropriate, but wait 6 weeks if angioedema occurred)